跳至主要内容
临床试验/NCT06402188
NCT06402188进行中(未招募)不适用

European ColoSeal™ ICD System Safety and Feasibility Study

Averto Medical, Inc.7 个研究点 分布在 3 个国家目标入组 90 人开始时间: 2023年6月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
90
试验地点
7
主要终点
Number of participants with device related adverse events

研究概览

简要总结

The studies aim to evaluate the safety and feasibility of the ColoSeal Intraluminal Colonic Diversion (ICD) System in two prospective, multicenter, single-arm studies. The ColoSeal ICD System is intended to be used to protect a damaged segment of colon such as a surgical anastomosis, anastomosis leak, or perforation from contact with fecal flow for up to 14 days. The device will be evaluated in adult patients with rectal and rectosigmoid cancer undergoing a resection with a colorectal anastomosis.

详细描述

The studies aim to evaluate the safety and feasibility of the ColoSeal Intraluminal Colonic Diversion (ICD) System in two prospective, multicenter, single-arm studies conducted under identical protocols. The ColoSeal ICD System is intended to be used to protect a damaged segment of colon such as a surgical anastomosis, anastomosis leak, or perforation from contact with fecal flow for up to 14 days. The device will be evaluated in adult patients with rectal and rectosigmoid cancer undergoing a resection with a colorectal anastomosis. Subjects will undergo scheduled resection per the surgeon's preferred technique. Following completion of the colon anastomosis, a leak check will be performed prior to insertion of the ColoSeal ICD Device to confirm no leak is present. The ICD Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The anchor portion is positioned > 5 cm above and ideally 10-20 cm above (more proximal in GI tract) the area requiring protection from fecal flow (the anastomosis). The anchor portion of the device is designed to be placed in healthy bowel and not at the region of damaged bowel where protection is required. After positioning, deployment, and anchoring of the ICD Device the Delivery System is removed. The external portion of the device is further anchored to the subject's skin using sutures and an optional extension tubing may be attached. A collection bag is attached to the end of the device to collect output. The ICD Device will remain in place for 10+/-3 days post-operatively. An anastomosis leak test will be performed prior to device removal. Once no leak is confirmed, the ICD Device is removed from the subject.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is 18-65 years of age at screening, or subject is 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.
  • Subject is diagnosed with rectosigmoid or rectal cancer
  • Subject is scheduled for elective resection, either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis and protective ostomy (anastomosis maximally 15 cm from the anal verge).
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).
  • Subject must be willing and able to comply with study follow-up requirements.

排除标准

  • Subject with a life expectancy < 1 year
  • Subjects with ASA classification > 3
  • Albumin < 30 g/liter
  • Subject has local or systemic infection at the time of intervention.
  • Major surgical or interventional procedures within 30 days prior to this study or planned major surgical or interventional procedures within 1 month of entry into this study
  • Patient has received systemic chemotherapy or radiation to the pelvis within 30 days prior to the planned procedure
  • Subject has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis, diverticulitis, or extensively spread inflammatory bowel disease
  • Subject has an anatomic abnormality (e.g., polyp, diverticula, vascular malformation) or bowel damage at or within 5 cm of the target device anchor site that could interfere with safe device function
  • Subjects has a diagnosis of coagulopathy, thrombocytopenia, immune suppression
  • Subject is scheduled for a concurrent major surgical procedure during the surgery (e.g., liver resection)
  • Subject has been taking regular systemic/ steroid medication in the last 3 months
  • Subjects is taking antimetabolites or antiplatelet agents (with the exception of aspirin)
  • Subject has undergone a prior pelvic anastomosis
  • Subject requires an end-to-end anastomosis smaller than 31 mm in diameter
  • Inadequate bowel preparation prior to the procedure
  • Anastomotic leak detected during intraoperative leak testing
  • Known allergy to any component of the device
  • Known allergy to iodine or iodine-based contrast unless subject can be adequately premedicated prior to leak test
  • Subject has unresolved alcohol abuse or illegal drug use
  • Any condition or abnormality which in the opinion of the investigator may jeopardize the subject's safe participation or the quality of the data
  • Subject is pregnant or planning to become pregnant. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure
  • Subject is unable or unwilling to provide informed consent
  • Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints

研究组 & 干预措施

ColoSeal ICD Device Treatment Arm

Experimental

Subjects will undergo transanal placement of the ICD Device.

干预措施: ColoSeal ICD Device (Device)

结局指标

主要结局

Number of participants with device related adverse events

时间窗: 90 days post procedure

Any device related adverse events during procedure and/or follow-up

次要结局

  • Successful device removal(Up to 21 days)
  • Procedure success(Day 0)
  • Migration rate(Up to 21 days)
  • Occurrence of anastomotic leakage(Up to 90 days post procedure)
  • Need for ostomy surgery(Up to 90 days post procedure)
  • Procedure time(Day 0)

研究者

发起方
Averto Medical, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验